BioLASCO Taiwan Co., Ltd. (TPEX:6662)

Market Cap	761.96M -16.0%
Revenue (ttm)	277.12M -4.7%
Net Income	44.74M +5.3%
EPS	1.75 +5.8%
Shares Out	25.61M
PE Ratio	17.03
Forward PE	n/a
Dividend	1.50 (5.06%)
Ex-Dividend Date	Aug 7, 2025

Volume	16,815
Average Volume	16,864
Open	30.40
Previous Close	29.65
Day's Range	29.30 - 30.40
52-Week Range	29.30 - 36.70
Beta	0.17
RSI	37.45
Earnings Date	Mar 20, 2026

About BioLASCO Taiwan

BioLASCO Taiwan Co., Ltd. operates an animal breeding center to produce specific pathogen-free laboratory mice and rats in Taiwan and internationally. It offers lab animals, such as rat, mice, and others, as well as surgical services; rodents housing, washing solutions, workstations, animal housing and management solutions, lab animal research equipment, clean solution, preclinical imaging system, and experimental equipment; various reagents, including lab animal diagnostic reagent, endotoxin testing system, portable endotoxin testing system, r...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 91
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6662

Financial Performance

In 2024, BioLASCO Taiwan's revenue was 292.50 million, an increase of 10.49% compared to the previous year's 264.72 million. Earnings were 44.03 million, a decrease of -11.49%.